Affinity Asset Advisors’s Prelude Therapeutics PRLD Stock Holding History

Affinity Asset Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.2M	Buy	+2,600,000	New	+$12.8M	0.41%	54

Other funds holding PRLD

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Affinity Asset Advisors's PRLD Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Prelude Therapeutics (PRLD) in Q3 2026: 2,600,000 shares worth $10.2M. The stake represents 0.41% of the portfolio and ranks #54 among its holdings.

59 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

Affinity Asset Advisors held 2,600,000 shares of Prelude Therapeutics worth $10.2M as of Q3 2026.
Prelude Therapeutics was a new Affinity Asset Advisors position in Q3 2026.
Prelude Therapeutics made up 0.41% of Affinity Asset Advisors's portfolio in Q3 2026, its #54 holding.
59 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.